Sage Journals: Discover world-class research

Abstract

Background:

Recent basic and clinical evidence suggests amiloride may be neuroprotective in multiple sclerosis (MS) through the blockade of the acid sensing ion channel (ASIC).

Objective:

To examine the neuroprotective efficacy of amiloride in acute optic neuritis (ON).

Methods:

A total of 48 patients were recruited to a phase 2, double blind, single site, randomised controlled trial. Scanning laser polarimetry (GDx) at 6 months was the primary outcome measure and optical coherence tomography (OCT) and visual and electrophysiological measures were secondary outcome measures. Participants aged 18–55 years, ≤28 days of onset of first episode unilateral ON, were randomised to amiloride (10 mg daily for 5 months) or placebo (clinicaltrials.gov, NCT 01802489).

Results:

Intention-to-treat (ITT) cohort consisted of 43 patients; 23 placebo and 20 amiloride. No significant drug-related adverse events occurred. No significant differences were found in GDx (p = 0.840). Visual evoked potentials (VEP) were significantly prolonged in the amiloride group compared to placebo (p = 0.004). All other secondary outcome measures showed no significant difference. Baseline analysis of OCT data demonstrated a significant pre-randomisation thinning of ganglion cell layer.

Conclusion:

Amiloride has not demonstrated any neuroprotective benefit within this trial paradigm, but future neuroprotective trials in ON should target the window of opportunity to maximise potential neuroprotective benefit.

Keywords

Clinical trial outcome measurement multiple sclerosis axonal loss

Get full access to this article

View all access options for this article.

References

Dendrou

Fugger

Friese

MA.

Immunopathology of multiple sclerosis. Nat Rev Immunol 2015; 15: 545–558.

Friese

Schattling

Fugger

Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat Rev Neurol 2014; 10: 225–238.

Stys

PK.

General mechanisms of axonal damage and its prevention. J Neurol Sci 2005; 233: 3–13.

Xiong

Zhu

Chu

et al . Neuroprotection in ischemia: Blocking calcium-permeable acid-sensing ion channels. Cell 2004; 118: 687–698.

Vergo

Craner

Etzensperger

et al . Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model. Brain 2011; 134: 571–584.

Friese

Craner

Etzensperger

et al . Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system. Nat Med 2007; 13: 1483–1489.

Arun

Tomassini

Sbardella

et al . Targeting ASIC1 in primary progressive multiple sclerosis: Evidence of neuroprotection with amiloride. Brain 2013; 136: 106–115.

Aktas

Albrecht

Hartung

HP.

Optic neuritis as a phase 2 paradigm for neuroprotection therapies of multiple sclerosis: Update on current trials and perspectives. Curr Opin Neurol 2016; 3: 199–204.

Suhs

Hein

Sattler

et al . A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol 2012; 72: 199–210.

10.

Cadavid

Balcer

Galetta

et al . Safety and efficacy of opicinumab in acute optic neuritis (RENEW): A randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2017; 16: 189–199.

11.

Pau

Al Zubidi

Yalamanchili

et al . Optic neuritis. Eye 2011; 25: 833–842.

12.

Kapoor

Miller

Jones

et al . Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritis. Neurology 1998; 50: 230–237.

13.

Syc

Saidha

Newsome

et al . Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. Brain 2012; 135: 521–533.

14.

Trip

Schlottmann

Jones

et al . Scanning laser polarimetry quantification of retinal nerve fiber layer thinning following optic neuritis. J Neuroophthalmol 2010; 30: 235–242.

15.

Raftopoulos

Hickman

Toosy

et al . Phenytoin for neuroprotection in patients with acute optic neuritis: A randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2016; 15: 259–269.

16.

Esfahani

Harandi

Movasat

et al . Memantine for axonal loss of optic neuritis. Graefes Arch Clin Exp Ophthalmol 2012; 250: 863–869.

17.

McKee

Elston

Evangelou

et al . Amiloride Clinical Trial In Optic Neuritis (ACTION) protocol: A randomised, double blind, placebo controlled trial. BMJ Open 2015; 5: e009200.

18.

Costello

Hodge

Pan

et al . Tracking retinal nerve fiber layer loss after optic neuritis: A prospective study using optical coherence tomography. Mult Scler 2008; 14: 893–905.

19.

Frohman

Dwyer

Frohman

et al . Relationship of optic nerve and brain conventional and non-conventional MRI measures and retinal nerve fiber layer thickness, as assessed by OCT and GDx: A pilot study. J Neurol Sci 2009; 282: 96–105.

20.

Tewarie

Balk

Costello

et al . The OSCAR-IB consensus criteria for retinal OCT quality assessment. PLoS ONE 2012; 7: e34823.

21.

Bach

Brigell

Hawlina

et al . ISCEV standard for clinical pattern electroretinography (PERG): 2012 update. Documenta Ophthalmologica 2013; 126: 1–7.

22.

Odom

Bach

Brigell

et al . ISCEV standard for clinical visual evoked potentials (2009 update). Doc Ophthalmol 2010; 120: 111–119.

23.

Keltner

Johnson

Spurr

et al . Baseline visual field profile of optic neuritis. The experience of the optic neuritis treatment trial. Optic Neuritis Study Group. Arch Ophthalmol 1993; 111: 231–234.

24.

Farnsworth

The Farnsworth-Munsell 100-hue and dichotomous tests for color vision. J Opt Soc Am 1943; 33: 568–578.

25.

Storoni

Pittock

Weinshenker

et al . Optic neuritis in an ethnically diverse population: Higher risk of atypical cases in patients of African or African-Caribbean heritage. J Neurol Sci 2012; 312: 21–25.

26.

Hickman

Dalton

Miller

et al . Management of acute optic neuritis. Lancet 2002; 360: 1953–1962.

27.

Wakakura

Minei-Higa

Oono

et al . Baseline features of idiopathic optic neuritis as determined by a multicenter treatment trial in Japan. Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG). Jpn J Ophthalmol 1999; 43: 127–132.

28.

Tsakiri

Kallenbach

Fuglo

et al . Simvastatin improves final visual outcome in acute optic neuritis: A randomized study. Mult Scler 2012; 18: 72–81.

29.

Costello

Pan

Yeh

et al . The temporal evolution of structural and functional measures after acute optic neuritis. J Neurol Neurosurg Psychiatry 2015; 86: 1369–1373.

30.

Kupersmith

Garvin

Wang

et al . Retinal ganglion cell layer thinning within one month of presentation for optic neuritis. Mult Scler 2016; 22: 641–648.

31.

Gabilondo

Martinez-Lapiscina

Fraga-Pumar

et al . Dynamics of retinal injury after acute optic neuritis. Ann Neurol 2015; 77: 517–528.

32.

Saver

JL.

Time is brain – Quantified. Stroke 2006; 37: 263–266.

33.

Cramer

Modvig

Simonsen

et al . Permeability of the blood–brain barrier predicts conversion from optic neuritis to multiple sclerosis. Brain 2015; 138: 2571–2583.

34.

Jones

Brusa

Neurophysiological evidence for long-term repair of MS lesions: Implications for axon protection. J Neurol Sci 2003; 206: 193.

35.

Gregory

Dendrou

Attfield

et al . TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 2012; 488: 508–511.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.14 MB

0.50 MB

0.00 MB

Amiloride does not protect retinal nerve fibre layer thickness in optic neuritis in a phase 2 randomised controlled trial

Abstract

Background:

Objective:

Methods:

Results:

Conclusion:

Keywords

Get full access to this article

References

Supplementary Material